NDA 211962/S-003

SUPPLEMENT APPROVAL

Xellia Pharmaceuticals, ApS
c/o Xellia Pharmaceuticals USA, LLC
Attention: Mark Kopulos
Senior Director Regulatory Affairs
2150 E Lake Cook Rd, Suite 1015
Buffalo Grove IL USA 60089

Dear Mr. Kopulos:

Please refer to your supplemental new drug application (sNDA) dated December 13, 2019 received December 13, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Vancomycin Injection, 500 mg/100 mL, 1 g/200 mL, 1.5 g/300 mL and 2 g/400 mL, Ready to Use (RTU).

This "Changes Being Effected" supplemental new drug application provides for the following changes:

- Addition of USP in applicant's drug product name since the product is fully in alignment with USP monograph Vancomycin Injection.
- Change of Xellia Pharmaceuticals USA, LLC headquarters' address (in labeling).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eva Zuffova, MS, PhD, Regulatory Project Manager, at (301) 796-0697.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

EVA ZUFFOVA
09/03/2020 02:02:22 PM

DMITRI IARIKOV
09/03/2020 02:31:51 PM